Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.

Abstract	This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.
Authors	Neal D Shore, Paul Sieber, Leanne Schimke, Adam Perzin, Scott Olsen
Journal	Urologic nursing (Urol Nurs) 2013 Sep-Oct Vol. 33 Issue 5 Pg. 236-44, 248 ISSN: 1053-816X [Print] United States
PMID	24354113 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Antineoplastic Agents, Hormonal Triptorelin Pamoate Gonadotropin-Releasing Hormone Leuprolide
Topics	Aged Aged, 80 and over Antineoplastic Agents, Hormonal (administration & dosage, adverse effects) Cross-Over Studies Gonadotropin-Releasing Hormone (agonists) Humans Leuprolide (administration & dosage, adverse effects) Male Middle Aged Prostatic Neoplasms (drug therapy, nursing) Triptorelin Pamoate (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!